Our Portfolio

Emalex Biosciences

Portfolio Link Arrow emalexbiosciences.com
  • THEME

    Growth Capital

  • STATUS

    active

Emalex Biosciences was created by Paragon Biosciences to develop new treatments for central nervous system disorders. Emalex is in late-stage development of a new class of drug targeting the D1 receptor for patients with Tourette syndrome and other conditions that have limited treatment options. Visit https://emalexbiosciences.com to learn more.

 

Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.

_